Aberrant expression of BCL11B in mycosis fungoides and its potential role in interferon-induced apoptosis
Xiaoguang Gu
Department of Dermatology and Venerology, Peking University First Hospital, Beijing, China
These authors contributed equally to this manuscript.
Search for more papers by this authorYang Wang
Department of Dermatology and Venerology, Peking University First Hospital, Beijing, China
These authors contributed equally to this manuscript.
Search for more papers by this authorGaolei Zhang
Department of Dermatology and Venerology, Peking University First Hospital, Beijing, China
Search for more papers by this authorWeiwei Li
Department of Dermatology and Venerology, Peking University First Hospital, Beijing, China
Search for more papers by this authorCorresponding Author
Ping Tu
Department of Dermatology and Venerology, Peking University First Hospital, Beijing, China
Correspondence: Ping Tu, M.D., Department of Dermatology and Venerology, Peking University First Hospital, 8 Xi Shiku Street, Xi Cheng District, Beijing 100034, China. Email: [email protected]Search for more papers by this authorXiaoguang Gu
Department of Dermatology and Venerology, Peking University First Hospital, Beijing, China
These authors contributed equally to this manuscript.
Search for more papers by this authorYang Wang
Department of Dermatology and Venerology, Peking University First Hospital, Beijing, China
These authors contributed equally to this manuscript.
Search for more papers by this authorGaolei Zhang
Department of Dermatology and Venerology, Peking University First Hospital, Beijing, China
Search for more papers by this authorWeiwei Li
Department of Dermatology and Venerology, Peking University First Hospital, Beijing, China
Search for more papers by this authorCorresponding Author
Ping Tu
Department of Dermatology and Venerology, Peking University First Hospital, Beijing, China
Correspondence: Ping Tu, M.D., Department of Dermatology and Venerology, Peking University First Hospital, 8 Xi Shiku Street, Xi Cheng District, Beijing 100034, China. Email: [email protected]Search for more papers by this authorConflict of interest: The authors have no conflict of interest to declare.
Abstract
BCL11B is a Kruppel-like C2H2-type zinc finger transcription factor, which has been associated with several human malignancies. Recent evidence showed that overexpressed BCL11B conferred chemoresistance to malignant T cells and that inhibiting BCL11B led to increased apoptosis, suggesting its potential pathogenic relevance in cutaneous T-cell lymphomas (CTCL), which were characterized by the resistance to chemotherapy-induced apoptosis. To investigate the expression pattern of BCL11B in different stages of mycosis fungoides (MF), quantitative reverse transcription polymerase chain reaction and immunohistochemistry were performed to compare the mRNA and protein expression among different stages of MF and benign inflammatory dermatoses (BID), respectively. BCL11B demonstrated significant upregulation in all stages of MF, compared with BID, in both mRNA expression level and protein level. In addition, BCL11B expression increased with advancing lesion tumor stage and overall disease stage. Further, to evaluate the dynamic expression of BCL11B under CTCL-directed treatment, BCL11B expression and cell apoptosis were evaluated after interferon (IFN)-α-2b and methotrexate treatment on CTCL cell line Hut78 cells. IFN-α-2b, but not methotrexate, induced BCL11B inhibition and cell apoptosis, suggesting that BCL11B may play important roles in the anti-CTCL effect of IFN-α-2b. In conclusion, our study demonstrated the overexpression of BCL11B in MF lesions and its potential relevance to disease progression. In addition, we provided evidence for BCL11B inhibitory approaches as a potential treatment to target chemoresistant tumor cells in advanced MF.
References
- 1Hwang ST, Janik JE, Jaffe ES, Wilson WH. Mycosis fungoides and Sezary syndrome. Lancet 2008; 371 (9616): 945–957.
- 2Willemze R, Jaffe ES, Burg G et al. WHO-EORTC classification for cutaneous lymphomas. Blood 2005; 105 (10): 3768–3785.
- 3Olsen E, Vonderheid E, Pimpinelli N et al. Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). Blood 2007; 110 (6): 1713–1722.
- 4Arai E, Katayama I, Ishihara K. Mycosis fungoides and Sezary syndrome in Japan. Clinicopathologic study of 107 autopsy cases. Pathol Res Pract 1991; 187 (4): 451–457.
- 5Campbell JJ, Clark RA, Watanabe R, Kupper TS. Sezary syndrome and mycosis fungoides arise from distinct T-cell subsets: a biologic rationale for their distinct clinical behaviors. Blood 2010; 116 (5): 767–771.
- 6van Doorn R, van Kester MS, Dijkman R et al. Oncogenomic analysis of mycosis fungoides reveals major differences with Sezary syndrome. Blood 2009; 113 (1): 127–136.
- 7Wang Y, Su M, Zhou LL et al. Deficiency of SATB1 expression in Sezary cells causes apoptosis resistance by regulating FasL/CD95L transcription. Blood 2011; 117 (14): 3826–3835.
- 8Avram D, Fields A, Pretty On Top K, Nevrivy DJ, Ishmael JE, Leid M. Isolation of a novel family of C(2)H(2) zinc finger proteins implicated in transcriptional repression mediated by chicken ovalbumin upstream promoter transcription factor (COUP-TF) orphan nuclear receptors. J Biol Chem 2000; 275 (14): 10315–10322.
- 9Liu P, Li P, Burke S. Critical roles of Bcl11b in T-cell development and maintenance of T-cell identity. Immunol Rev 2010; 238 (1): 138–149.
- 10Albu DI, Feng D, Bhattacharya D et al. BCL11B is required for positive selection and survival of double-positive thymocytes. J Exp Med 2007; 204 (12): 3003–3015.
- 11Wakabayashi Y, Watanabe H, Inoue J et al. Bcl11b is required for differentiation and survival of alphabeta T lymphocytes. Nat Immunol 2003; 4 (6): 533–539.
- 12Li P, Burke S, Wang J et al. Reprogramming of T cells to natural killer-like cells upon Bcl11b deletion. Science 2010; 329 (5987): 85–89.
- 13Salgado R, Servitje O, Gallardo F et al. Oligonucleotide array-CGH identifies genomic subgroups and prognostic markers for tumor stage mycosis fungoides. J Invest Dermatol 2010; 130 (4): 1126–1135.
- 14Sakata J, Inoue J, Ohi H et al. Involvement of V (D) J recombinase in the generation of intragenic deletions in the Rit1/Bcl11b tumor suppressor gene in gamma-ray-induced thymic lymphomas and in normal thymus of the mouse. Carcinogenesis 2004; 25 (6): 1069–1075.
- 15Wakabayashi Y, Inoue J, Takahashi Y et al. Homozygous deletions and point mutations of the Rit1/Bcl11b gene in gamma-ray induced mouse thymic lymphomas. Biochem Biophys Res Commun 2003; 301 (2): 598–603.
- 16Gutierrez A, Kentsis A, Sanda T et al. The BCL11B tumor suppressor is mutated across the major molecular subtypes of T-cell acute lymphoblastic leukemia. Blood 2011; 118 (15): 4169–4173.
- 17De Keersmaecker K, Real PJ, Gatta GD et al. The TLX1 oncogene drives aneuploidy in T cell transformation. Nat Med 2010; 16 (11): 1321–1327.
- 18Kamimura K, Ohi H, Kubota T et al. Haploinsufficiency of Bcl11b for suppression of lymphomagenesis and thymocyte development. Biochem Biophys Res Commun 2007; 355 (2): 538–542.
- 19Huang X, Chen S, Shen Q et al. Analysis of the expression pattern of the BCL11B gene and its relatives in patients with T-cell acute lymphoblastic leukemia. J Hematol Oncol 2010; 3 (1): 44.
- 20Oshiro A, Tagawa H, Ohshima K et al. Identification of subtype-specific genomic alterations in aggressive adult T-cell leukemia/lymphoma. Blood 2006; 107 (11): 4500–4507.
- 21Fujimoto R, Ozawa T, Itoyama T, Sadamori N, Kurosawa N, Isobe M. HELIOS-BCL11B fusion gene involvement in a t (2;14) (q34;q32) in an adult T-cell leukemia patient. Cancer Genet 2012; 8: 356–364.
- 22MacLeod RA, Nagel S, Kaufmann M, Janssen JW, Drexler HG. Activation of HOX11L2 by juxtaposition with 3′-BCL11B in an acute lymphoblastic leukemia cell line (HPB-ALL) with t (5;14) (q35;q32.2). Genes Chromosom Cancer 2003; 37 (1): 84–91.
- 23Grabarczyk P, Nahse V, Delin M et al. Increased expression of bcl11b leads to chemoresistance accompanied by G1 accumulation. PLoS ONE 2010; 5 (9): e12532.
- 24Su MW, Dorocicz I, Dragowska WH et al. Aberrant expression of T-plastin in Sezary cells. Cancer Res 2003; 63 (21): 7122–7127.
- 25Tracey L, Villuendas R, Ortiz P et al. Identification of genes involved in resistance to interferon-alpha in cutaneous T-cell lymphoma. Am J Pathol 2002; 161 (5): 1825–1837.
- 26Wu J, Wood GS. Reduction of Fas/CD95 promoter methylation, upregulation of Fas protein, and enhancement of sensitivity to apoptosis in cutaneous T-cell lymphoma. Arch Dermatol 2011; 147 (4): 443–449.
- 27Girardi M, Heald PW, Wilson LD. The pathogenesis of mycosis fungoides. N Engl J Med 2004; 350 (19): 1978–1988.
- 28Golonzhka O, Liang X, Messaddeq N et al. Dual role of COUP-TF-interacting protein 2 in epidermal homeostasis and permeability barrier formation. J Invest Dermatol 2009; 129 (6): 1459–1470.
- 29Yanase N, Kanetaka Y, Mizuguchi J. Interferon-alpha-induced apoptosis via tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-dependent and -independent manner. Oncol Rep 2007; 18 (4): 1031–1038.
- 30Yanase N, Hata K, Shimo K, Hayashida M, Evers BM, Mizuguchi J. Requirement of c-Jun NH2-terminal kinase activation in interferon-alpha-induced apoptosis through upregulation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) in Daudi B lymphoma cells. Exp Cell Res 2005; 310 (1): 10–21.
- 31Du LQ, Du XQ, Bai JQ et al. Methotrexate-mediated inhibition of RAD51 expression and homologous recombination in cancer cells. J Cancer Res Clin Oncol 2012; 138 (5): 811–818.
- 32Wu J, Nihal M, Siddiqui J, Vonderheid EC, Wood GS. Low FAS/CD95 expression by CTCL correlates with reduced sensitivity to apoptosis that can be restored by FAS upregulation. J Invest Dermatol 2009; 129 (5): 1165–1173.
- 33Frei GM, Kremer M, Hanschmann KM et al. Antitumour effects in mycosis fungoides of the immunomodulatory, tellurium-based compound, AS101. Br J Dermatol 2008; 158 (3): 578–586.
- 34Klemke CD, Brenner D, Weiss EM et al. Lack of T-cell receptor-induced signaling is crucial for CD95 ligand up-regulation and protects cutaneous T-cell lymphoma cells from activation-induced cell death. Cancer Res 2009; 69 (10): 4175–4183.
- 35Cismasiu VB, Adamo K, Gecewicz J, Duque J, Lin Q, Avram D. BCL11B functionally associates with the NuRD complex in T lymphocytes to repress targeted promoter. Oncogene 2005; 24 (45): 6753–6764.
- 36Cismasiu VB, Duque J, Paskaleva E et al. BCL11B enhances TCR/CD28-triggered NF-kappaB activation through up-regulation of Cot kinase gene expression in T-lymphocytes. Biochem J 2009; 417 (2): 457–466.
- 37Cismasiu VB, Ghanta S, Duque J et al. BCL11B participates in the activation of IL2 gene expression in CD4+ T lymphocytes. Blood 2006; 108 (8): 2695–2702.
- 38Zhang S, Rozell M, Verma RK et al. Antigen-specific clonal expansion and cytolytic effector function of CD8+ T lymphocytes depend on the transcription factor Bcl11b. J Exp Med 2010; 207 (8): 1687–1699.
- 39Chen S, Huang X, Yang L et al. The role of BCL11B in regulating the proliferation of human naive T cells. Hum Immunol 2012; 73 (5): 456–464.
- 40Grabarczyk P, Przybylski GK, Depke M et al. Inhibition of BCL11B expression leads to apoptosis of malignant but not normal mature T cells. Oncogene 2007; 26 (26): 3797–3810.
- 41Olsen EA. Interferon in the treatment of cutaneous T-cell lymphoma. Dermatol Ther 2003; 16 (4): 311–321.
- 42Schindler C, Levy DE, Decker T. JAK-STAT signaling: from interferons to cytokines. J Biol Chem 2007; 282 (28): 20059–20063.
- 43Shibata T, Shimada Y, Shimoyama M. Time-dependent cytotoxic action of human recombinant alpha-interferon (Ro22-8181) in vitro and the sensitivity of various cultured leukemia and lymphoma cell lines to it. Jpn J Clin Oncol 1985; 15 (1): 67–75.
Citing Literature
